Featured coverage image. Source: Editorial desk.
Researchers at the National University of Singapore have discovered a master switch gene called DP103 and an investigational drug that can halt aggressive triple-negative breast cancer growth.
Researchers at the National University of Singapore have discovered a master switch gene called DP103 and an investigational drug that can halt aggressive triple-negative breast cancer growth.
Singapore, August 23, 2026 – In a landmark discovery poised to transform the landscape of breast cancer treatment, researchers from the National University of Singapore (NUS) Yong Loo Lin School of Medicine have identified a crucial "master switch" responsible for driving tumor growth in triple-negative breast cancer (TNBC). This groundbreaking finding, coupled with the identification of a drug capable of deactivating this switch, offers a beacon of hope for patients grappling with one of the most aggressive and challenging forms of breast cancer.
Published in the esteemed journal Cell Death and Disease, this research represents a significant leap forward in precision oncology, offering a new therapeutic avenue where options have historically been limited. The discovery promises more targeted and personalized treatments, potentially altering the prognosis for countless individuals worldwide.
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that accounts for approximately 15% to 20% of all breast cancer diagnoses and is notoriously difficult to treat due to its unique molecular profile and high propensity for recurrence and metastasis. Unlike other breast cancers, TNBC cells lack the three most common receptors—estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2)—which are typically targeted by conventional therapies. This absence leaves patients with fewer targeted treatment options, often relying on chemotherapy, surgery, and radiation, which may not be effective for all, and resistance is common. TNBC disproportionately affects women under the age of 40 and is associated with an elevated risk of early recurrence, metastasis, and a poorer survival rate.
For years, researchers have grappled with the elusive mechanisms that empower TNBC cells to grow aggressively, spread rapidly, and resist existing treatments. The NUS Medicine team, spearheaded by Research Assistant Professor Alan Prem Kumar from the NUS Centre for Cancer Research (N2CR) and Department of Pharmacology, NUS Medicine, focused their investigations on understanding how these tenacious cancer cells not only survive but also fuel tumor regrowth through a small population of cancer stem cells.
Their diligent research led to the identification of a previously unknown "master regulator" gene, named DP103. This gene plays a pivotal role in orchestrating a self-reinforcing cycle that drives aggressive tumor growth, promotes the spread of cancer cells, and enhances their resistance to therapy. Crucially, DP103 also sustains the population of cancer stem cells, which are often the culprits behind disease recurrence.
Associate Professor Celestial T. Yap, a clinician-scientist from N2CR and Department of Physiology, NUS Medicine, and a co-author of the study, emphasized the significance of this finding. "Triple-negative breast cancer remains particularly difficult to treat because standard options such as surgery, chemotherapy, and immunotherapy do not work equally well for all patients, and resistance and recurrence are common," she noted. "What makes this finding exciting is that DP103 may represent a new biological vulnerability in the disease, linking tumour growth, stemness, and treatment resistance."
The team discovered that DP103 achieves its master regulatory function by reinforcing the activity of the Wnt signalling pathway. The Wnt/β-catenin signalling pathway is a fundamental biological system that controls various cellular processes, including cell growth and movement. While essential for normal development, its aberrant activation can become a significant driver of cancer progression. The NUS researchers observed that DP103 creates a molecular circuit that not only sustains Wnt/β-catenin activity but also preserves the dangerous cancer stem-cell state, encourages tumor cell division, and helps them evade programmed cell death, thereby acquiring traits associated with invasion.
With the identification of DP103 as the critical "master switch," the next challenge was to find a way to turn it off. The research team rigorously evaluated whether an investigational targeted drug, known as Supinoxin (or RX-5902), could effectively block the effects of DP103 in driving triple-negative breast cancer.
Dr. Cai Wanpei, the first author of the study and a former PhD student at N2CR and Department of Pharmacology, NUS Medicine, explained the drug's mechanism. "The RX-5902 drug is a first-in-class oral targeted therapy designed to block a key cancer-promoting pathway known as Wnt/β-catenin," she stated. "By preventing β-catenin from entering the cell nucleus, the drug switches off genes that drive cancer growth, spread and survival. This slows tumour progression and triggers apoptosis – the natural death of cancer cells."
The results from preclinical studies were remarkably promising. The researchers analyzed 21 samples, including patient tumor tissue, laboratory-grown breast cancer cells, and organoids derived from local cancer patients. In these analyses, RX-5902 demonstrated a significant impact:
| Research Outcome | Effect | Details |
|---|---|---|
| Cancer Stem Cell Viability | Reduced by 40% to 60% | The drug substantially decreased the survival of cancer stem cells, which are key to tumor regrowth and treatment resistance. |
| Tumor Growth (Laboratory-grown models) | Fell by approximately 50% | In controlled laboratory settings using cultured tumor models, the drug effectively halved tumor expansion. |
| Tumor Size (Laboratory animal models) | Reduced by around 90% | In more complex in vivo models, RX-5902 led to a dramatic reduction in tumor size, while largely sparing healthy cells, indicating its targeted nature and potential for reduced side effects compared to broad-acting chemotherapies. |
| Survival Extension (Laboratory animal models) | 50% reached 70+ days versus none in untreated | A significant proportion of treated models survived considerably longer than their untreated counterparts, highlighting the drug's potential to extend patient lifespan by disrupting the molecular conditions that support tumor-cell survival and self-renewal. |
These findings collectively suggest that RX-5902 could do more than temporarily slow cancer progression; by disrupting the core molecular machinery sustaining TNBC, it could weaken the very reservoir of cells responsible for recurrence and metastasis.
The NUS Medicine team's discovery not only provides a potential new treatment but also offers a crucial diagnostic tool. Research Assistant Professor Alan Prem Kumar highlighted this dual benefit: "Patients with triple-negative breast cancer are facing an aggressive form of breast cancer with limited treatment options. Our findings suggest that DP103 could potentially serve as a diagnostic biomarker to identify the patients most likely to benefit from RX-5902 treatment, paving the way for a more precise, personalised approach to treating triple-negative breast cancer." This means that instead of a one-size-fits-all approach, future clinical trials could be tailored to patients whose tumors exhibit high levels of DP103, maximizing the therapy's impact.
The path forward involves further rigorous evaluation of DP103 in larger patient cohorts. The researchers also plan to investigate combinations of RX-5902 with existing treatments like chemotherapy, immunotherapy, or other targeted agents. This combination therapy approach is particularly important given the biological diversity of TNBC, which often enables tumors to activate alternative survival mechanisms.
Moreover, the implications of this discovery may extend beyond breast cancer. Since abnormal Wnt activity is implicated in several other aggressive tumor types, DP103-driven Wnt signalling could be a relevant target in other forms of cancer, opening new avenues for research and treatment across different malignancies.
This breakthrough from NUS Medicine researchers marks a monumental step in the fight against triple-negative breast cancer. By understanding and targeting the "master switch" DP103 with the drug RX-5902, scientists have unveiled a new vulnerability in this aggressive disease. The promise of personalized medicine, where treatments are precisely matched to a patient's unique tumor profile, draws closer.
While clinical trials are still on the horizon, the preclinical data provides a strong foundation for optimism. This discovery offers not just a potential new drug, but a deeper understanding of TNBC's fundamental biology, paving the way for more effective, targeted, and ultimately, life-saving therapies for patients worldwide. The hope is that this research will translate into improved clinical outcomes, offering durable disease control and a renewed sense of possibility for those affected by triple-negative breast cancer.
Triple-negative breast cancer (TNBC) is particularly challenging because it lacks the three common receptors (estrogen, progesterone, and HER2 protein) that many standard breast cancer therapies target. This absence means hormone therapy and HER2-targeted drugs are ineffective, leaving fewer treatment options. TNBC is also an aggressive subtype, prone to early recurrence, metastasis, and resistance to conventional treatments.
The "master switch" is a gene identified as DP103 by researchers at NUS Medicine. DP103 acts as a key regulator in the Wnt signalling pathway, which is a critical process for cell growth and movement. In TNBC, DP103 creates a self-reinforcing cycle that drives tumor growth, helps cancer cells spread, and enables them to resist treatment, while also maintaining the population of cancer stem cells responsible for disease recurrence.
RX-5902, also known as Supinoxin, is an investigational oral targeted therapy designed to turn off the DP103 "master switch." It functions by blocking beta-catenin from entering the cell nucleus, which in turn switches off the genes that are responsible for driving cancer growth, spread, and survival. This mechanism effectively slows tumor progression and triggers apoptosis, or programmed cell death, in cancer cells, while largely sparing healthy cells.
This discovery holds significant promise for TNBC patients. The identification of DP103 as a potential diagnostic biomarker means that future treatments could be more personalized, targeting patients whose tumors show high levels of DP103. The drug RX-5902 could offer a much-needed targeted therapy where few exist. Researchers also plan to explore combination therapies and investigate if this approach could benefit other cancer types driven by similar mechanisms, potentially expanding its impact beyond breast cancer.
Featured image by Vitaly Gariev on Unsplash
AI BlogX is committed to high editorial standards. For time-sensitive or critical topics, please verify claims against original primary sources.
Authoritative and trend-focused coverage across business, sports, entertainment, health, lifestyle, politics, science, and technology.
More Desks
© 2026 AI BlogX. All rights reserved.
Trend-focused editorial workflow
Stories are monitored from trending signals, then processed for accurate summaries, fact-checking, and desk oversight.
Editorial policy
